|
English
|
正體中文
|
简体中文
|
0
|
|
???header.visitor??? :
53110668
???header.onlineuser??? :
942
???header.sponsordeclaration???
|
|
|
|
???tair.name??? >
???browser.page.title.author???
|
"akamatsu h"???jsp.browse.items-by-author.description???
Showing items 1-2 of 2 (1 Page(s) Totally)
1
View [10|25|50] records per page
| 國立成功大學 |
2020 |
Osimertinib versus platinum–pemetrexed for patients with EGFR T790M advanced NSCLC and progression on a prior EGFR-tyrosine kinase inhibitor: AURA3 overall survival analysis
|
Papadimitrakopoulou, V.A.;Mok, T.S.;Han, J.-Y.;Ahn, M.-J.;Delmonte, A.;Ramalingam, S.S.;Kim, S.W.;Shepherd, F.A.;Laskin, J.;He, Y.;Akamatsu, H.;Theelen, W.S.M.E.;Su, W.-C.;John, T.;Sebastian, M.;Mann, H.;Miranda, Miranda M.;Laus, G.;Rukazenkov, Y.;Wu, Y.-L. |
| 國立成功大學 |
2018 |
EGFR mutation analysis for prospective patient selection in AURA3 phase III trial of osimertinib versus platinum-pemetrexed in patients with EGFR T790M-positive advanced non-small-cell lung cancer
|
John, T.;Akamatsu, H.;Delmonte, A.;Su, W.-C.;Lee, J.S.;Chang, G.-C.;Huang, X.;Jenkins, S.;Wu, Y.-L. |
Showing items 1-2 of 2 (1 Page(s) Totally)
1
View [10|25|50] records per page
|
